Establishing privacy regarding medical treatments.
House Bill 2182 would create a new article in the West Virginia Code establishing a privacy right related to medical treatments. The bill says that, notwithstanding any other law, a person may not be required to take, be administered, or otherwise receive a medical product, or be required to disclose whether they have done so, unless the manufacturer of that product is liable for any death or serious injury caused by the product. The bill defines “medical product” broadly to include medical devices, drugs, and biologics.
In practical terms, the measure appears aimed at limiting mandatory medical interventions and related disclosure requirements. It would affect state law by adding a new statutory protection in Title 16, potentially constraining government, employer, school, or other mandates that require receipt of certain medical products, depending on how broadly the provision is interpreted and applied. It also ties the restriction to manufacturer liability for serious harm or death, which may create uncertainty about when a mandate would be permitted.
HB2182 would add a new section to West Virginia’s health code establishing a statutory privacy right concerning medical treatments and products. It could limit or complicate existing or future requirements involving vaccination, medication, medical devices, or disclosure of treatment status, and it would likely affect state agencies, employers, schools, healthcare providers, and other entities that impose or administer medical-product-related requirements. The bill’s liability-based exception could also interact with product liability law and federal or state public health rules.
No committee transcript or vote record is available for HB2182, so there is no documented debate or recorded vote to gauge legislative sentiment. Based on the bill text alone, the measure appears to reflect a pro-personal-autonomy and anti-mandate policy approach, emphasizing privacy and voluntary medical decision-making. Because the bill was introduced and referred to committee without further recorded action in the provided materials, its reception cannot be determined from the available record.
The main point of contention is likely the bill’s broad restriction on requiring medical products or disclosure of medical-product status, especially in settings where mandates are used for public health, workplace safety, school attendance, or healthcare access. Another likely dispute is the bill’s unusual condition that the prohibition applies unless the manufacturer is liable for death or serious injury, which may be difficult to interpret and could create uncertainty about enforcement. Supporters would likely frame the bill as protecting bodily autonomy and medical privacy, while opponents may argue it could undermine public health measures and create legal ambiguity.